Affimed Investor Relations Material
Latest events
Study Update
Affimed
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Affimed N.V.
Access all reports
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. The company operates through two segments, Affimed Therapeutics, and Redoxa GmbH. It develops therapies based on its proprietary TandAb platform to unleash the innate power of the immune system by harnessing the functionality of natural killer cells and T-cells for the treatment of cancer.
The company has strategic partnerships with Genentech Inc.; Merck KGaA and Pfizer Inc.; Novartis Institutes for BioMedical Research, Inc.; Celgene Corporation; Bayer Pharma AG; MorphoSys AG; Incyte Corporation; Amgen Inc.; Hoffmann-La Roche ltd; Sanofi S.A.; and Bristol-Myers Squibb Company. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany
Key slides for Affimed N.V.
Study Update
Affimed N.V.
Study Update
Affimed N.V.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
AFMD
Country
🇺🇸 United States